Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Introduction Excessive exposure to ultraviolet UV irradiatio
2019-12-24

Introduction Excessive exposure to ultraviolet (UV) irradiation from the sun injures human skin, which might lead to premature aging and skin pathologies [1], [2]. Chronic exposure to UV (especially ultraviolet-B, UVB) irradiation could profoundly affect the skin epidermis, interfering with the ker
-
Enzymatic assay The usual in vitro test
2019-12-24

Enzymatic assay. The usual in vitro test for the measure of the activity of DbH involves ascorbate as a cosubstrate (e.g., 5mM) and tyramine as a substrate (e.g., 10mM). When using N-aryl-N′-hydroxyguanidines instead of ascorbate, the hydroxylase activity of DbH was measured by HPLC as the amounts o
-
Total synthesis requires the two key intermediates and which
2019-12-24

Total synthesis requires the two key intermediates 3 and 7, which were synthesized using the route described in below. Phenylethylamine 3 was readily synthesized from vanillin or isovanillin; the overall yield was 50–52%. To prepare the intermediates 7, bromination of 2-(4-hydroxyphenyl) acetate wit
-
Cy3 carboxylic acid (non-sulfonated) receptor br STAR Method
2019-12-24

STAR★Methods Acknowledgments We thank Geneviève Almouzni, Sophie Polo, Ralph Scully, Wael Mansour, and Jeremy Stark for providing cell lines and Wolf Heyer, Haico van Attikum, Martijn Luijsterburg, and Brendan Price for helpful discussions. We thank Ratna Weimer, Bettina Basso, Christel Braun,
-
br Acknowledgements The research leading to these results ha
2019-12-23

Acknowledgements The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7-PEOPLE-2013-COFUND) under grant agreement no 609020 − Scientia Fellows (JB) and the Research Council of Norway (NFR-grant 221444) (JB, JPM, OB). Introduction Hu
-
WES and validation by Sanger sequencing in PNGS revealed an
2019-12-23

WES and validation by Sanger sequencing in PNGS-252 revealed an apparent homozygous c.4C>G missense alteration (GenBank: NM_014176.3), resulting in the amino vistusertib substitution p.Gln2Glu (Figure 1A). This mutation must be very rare, because this is not listed in the NHLBI Exome Sequencing Pro
-
br Results br Discussion In this paper
2019-12-23

Results Discussion In this paper we present insights into the observed specificities of inhibitors targeting the ubiquitin-activating and related E1 Carbenoxolone disodium via crystal structures of the specific NEDD8-E1 inhibitor MLN4924, the dual NEDD8/Ub E1 inhibitor ABPA3, and the selectiv
-
Protein degradation via UPP involves two steps One
2019-12-23

Protein degradation via UPP involves two steps. One step is the conjugation of multiple ubiquitin to a substrate. The other step is the degradation of tagged protein by the downstream 26S proteasome complex. Protein ubiquitination is the E1–E2–E3 enzymatic cascade (Hershko & Ciechanover, 1998). E1-a
-
Despite the significant increase in Bdnf mRNA
2019-12-23

Despite the significant increase in Bdnf1 mRNA levels after DNMT inhibition, the expression of Bdnf4 and Bdnf9 was unaltered. It is particularly surprising that Bdnf4 is not affected by the DNMT inhibitor, as the promoter of the Bdnf4 exon is known to be susceptible to epigenetic changes (Kotera et
-
AVE 0991 The use of SP in IPTp may not
2019-12-23

The use of SP in IPTp may not be the only driver of parasite polymorphisms in this population, because Senegal has used sulfadoxine and/or pyrimethamine in the national antimalarial treatment plan for many years, and furthermore these drugs are still being used in antibacterial combination therapy.
-
In this study CK C prepared from BL
2019-12-23

In this study, CK1δ(ΔC) prepared from BL21(DE3)pλPP had the highest kinase activity among the three isoforms tested when using casein as a substrate. Therefore, CK1δ(ΔC) from BL21(DE3)pλPP has the potential to be a “phosphorylating reagent” that may be widely used in experiments of phosphorylation a
-
740 Y-P Previous research has suggested that the acetylcholi
2019-12-23

Previous research has suggested that the acetylcholine-gated chloride channels (ACCs) in Caenorhabditis elegans (Putrenko et al., 2005) exhibit the characteristics of promising drug targets. The genes that encode the various subunits of this family are present across the nematode phylum and appear t
-
br Introduction Plasmodium falciparum malaria
2019-12-20

Introduction Plasmodium falciparum malaria continues to be a major global cause of mortality and morbidity. Malaria treatment and control has been complicated by the emergence of resistance to widespread antimalarial drug use. The most common method for measuring antimalarial resistance is estima
-
The present study provides the
2019-12-20

The present study provides the first evidence that the human uroepithelial Aripiprazole in vitro respond directly, within 48h, to this carcinogen by promoting extensive vacuolation and DAPK expression. By using the TEM, ICC and Western blotting, we found that the arsenite-induced vacuoles were deri
-
The field of synthetic cytokine
2019-12-20

The field of synthetic cytokine biology continues to grow through molecular, physiological and pathophysiological insights, as well as via new methodical advances. The approval of chimeric antigen receptor (CAR) T cell immunotherapy by the US Food and Drug administration (FDA) in August 2017 for rel
15756 records 893/1051 page Previous Next First page 上5页 891892893894895 下5页 Last page